

<b>NHS Greater Glasgow and Clyde</b>	<b>Paper No. 25/170</b>
<b>Paper Title:</b>	<b>Standing Committee Chair's Board Report</b>
<b>Meeting:</b>	<b>NHSGGC Board Meeting</b>
<b>Date of Meeting:</b>	<b>18 December 2025</b>
<b>Purpose of Paper:</b>	<b>For Assurance</b>
<b>Classification:</b>	<b>Board Official</b>
<b>Name of Reporting Committee:</b>	<b>Finance, Planning and Performance Committee</b>
<b>Date of Reporting Committee:</b>	<b>11 December 2025</b>
<b>Committee Chairperson:</b>	<b>Margaret Kerr, Chair of Committee</b>

## 1. Purpose of Paper

**The purpose of this paper is to:** inform the NHS Board on key items of discussion at the NHSGGC Finance, Planning and Performance Committee.

## 2. Recommendation

The Board is asked to note the key items of discussion at the recent meeting of the Finance, Planning and Performance Committee on 11 December 2025 as set out below and seek further assurance as required.

## 3. Key Items of Discussion

### 3.1 Financial Monitoring Report – Month 7

- The Committee received the report for assurance.
- The Committee were advised that as at 31 October 2025 an overspend of £45.0 million was reported. The Acute Division was overspent by £15.7 million and there was an underspend in Corporate of £12.1 million. Unachieved Sustainability and Value programme savings accounted for £45.9 million.
- The Sustainability and Value programme had delivered £123.5 million on an in-year basis which was just over 56% of the overall financial challenge. On a recurring basis just over 28% of the recurring target had been achieved. The

Committee noted that further initiatives would be required to meet the financial plan position of breakeven.

- The Committee noted that the total capital expenditure incurred to 31 October 2025 was £27.3 million, which amounted to 30% of the capital budget. £60.9 million (62%) of the total capital allocation had firm orders or had incurred spend which was in line with expectations.
- The Committee were advised that the projected deficit forecast for 2025/26 had reduced by £5.4 million to £39.6 million and noted the work underway to achieve a breakeven position by the end of the year.
- The Committee were content to note the report.

### **3.2 Performance Report including Cancer Performance**

- The Committee received the report for assurance.
- The Committee noted the key areas of performance challenges as well as the key areas of good performance over the period. The Committee discussed unscheduled care performance, absence management, MSK physiotherapy and the vaccination programme and were assured by the ongoing work to improve performance.
- The Committee were also provided with a comprehensive overview of cancer services in NHSGGC which described the challenges and the improvement actions that were underway.
- The Committee noted that there had been some improvement in 62 day performance since September 2025 with further actions underway to meet the trajectories and although the Committee were assured by the significant work that was underway it was acknowledged that more needed to be done to further improve the position.

### **3.3 Financial Plan (2026/27) - Update**

- The Committee received a presentation for assurance.
- The Committee were advised on the timescales and proposed governance around the 2026/27 financial plan, noting that the final timelines for submission were awaited from the Scottish Government.
- The Committee were assured by the update.

### **3.4 Strategies to Improve the Cost Effective Use of Medicines in NHSGGC**

- The Committee received the report for awareness.
- The Committee were advised on the strategies that were underway in Primary Care and the Acute Division to promote the cost effective use of medicines while maintaining safe, high quality care. The Committee noted that this was a significant work programme and were advised on the prioritisation of this work as well as the approaches to engagement with service management teams and healthcare professionals involved in the prescribing and administration of medicines.
- The Committee noted the report.

### **3.5 2025/26 Delivery Plan – Q2 Summary Report**

- The Committee received the report for assurance.
- The Committee were updated on progress against implementing the 123 actions set out in the 2025/26 Delivery Plan and noted that at the end of the quarter the majority of actions were on schedule or had been completed. The Committee

received a summary of the work underway to progress the actions where delivery was delayed or at risk.

- The Committee were assured by the report which would now be submitted to the Scottish Government.

### **3.6 Transforming Together – GGC Way Forward Report**

- The Committee received the report for endorsement.
- The Committee were advised that all six of NHSGGC's transformation programmes remained on track and had made positive progress as well as a summary of the key achievements across each programme
- The Committee were content to endorse the plan which would now be presented to the NHS Board on 18 December 2025.

### **3.7 Corporate Risk Register**

- The Committee received the report for approval.
- The Committee noted that 92% of the 12 risks that were assigned to the Committee had been reviewed in the last month with one change proposed to reduce the Financial Sustainability risk given the positive reduction in the projected financial deficit. The Committee noted that 25 actions remained overdue but were assured that work was ongoing to complete these. The Committee were also assured that the queries raised at the previous meeting of the Committee had been responded to.
- The Committee were content to approve the Corporate Risk Register.

## **4. Issues for referral to other Standing Committees or escalation to the NHS Board**

There were no issues for referral to other Standing Committees or escalation to the NHS Board.

## **5. Date of Next Meeting**

The next meeting of the Finance, Planning and Performance Committee is TBC subject to Board approval of the wider Committee membership.